Publication | Closed Access

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

GynecologyCervical Cancer PreventionHuman Papillomavirus VaccinesVaccine SurveillancePublic HealthVaccinologyVaccine SafetyCervical HealthVaccine TestingQuadrivalent Human PapillomavirusEpidemiologyRecombinant VaccineVaccinationCervical CancerDouble-blind TrialPrecision VaccinologyVaccine EfficacyMedicinePrecancerous Lesions